文献速递神经核医学放射性药物与辐射防护

[18F]FNDP PET神经影像的重测可重复性与人体全身剂量测定

[18F]FNDP PET neuroimaging test-retest repeatability and whole-body dosimetry in humans.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-07-17

研究在7名健康成人中评估[18F]FNDP脑PET区域总分布容积(VT)的重测可重复性,并在另6名健康成人中完成4.5小时全身PET/CT剂量测定。结果显示区域VT平均重测差异为0.82±5.17%,ICC为0.92–0.99,胆囊吸收剂量最高(0.081±0.024 mSv/MBq),有效剂量为0.020±0.003 mSv/MBq。

要点

  • 7名健康成人两次[18F]FNDP脑PET间隔14天内完成,区域VT重测可重复性良好。
  • 不同脑区ICC范围为0.92–0.99。
  • 全身剂量测定中胆囊吸收剂量最高,有效剂量为0.020±0.003 mSv/MBq。

核心结论

  • [18F]FNDP脑PET区域VT具有良好的重测可重复性,每次扫描对人体的辐射剂量与其他18F类PET放射性示踪剂相似。

研究设计与样本

  • 重测研究:7名健康成人(4男3女,年龄40.1±4.6岁)在14天内完成两次[18F]FNDP脑PET;另6名健康成人(3男3女,年龄46.0±7.0岁)接受[18F]FNDP PET/CT全身剂量测定,采集自给药后即刻起持续4.5小时。

主要发现

  • 区域VT平均重测差异(ΔVT)为0.82±5.17%,区域VT平均绝对差异为4.01±3.33%,不同脑区ICC范围为0.92–0.99;吸收剂量最高的器官为胆囊(0.081±0.024 mSv/MBq),其次为肝脏(0.077±0.018 mSv/MBq)和肾脏(0.063±0.006 mSv/MBq),有效剂量为0.020±0.003 mSv/MBq。

关键数值与推荐

  • 区域VT平均重测差异(ΔVT)为0.82±5.17%。
  • 区域VT平均绝对差异为4.01±3.33%。
  • 不同脑区ICC范围为0.92–0.99。
  • 胆囊吸收剂量为0.081±0.024 mSv/MBq,肝脏为0.077±0.018 mSv/MBq,肾脏为0.063±0.006 mSv/MBq。
  • 有效剂量为0.020±0.003 mSv/MBq。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Soluble epoxide hydrolase (sEH) is an enzyme that shapes immune signaling through its role in maintaining the homeostasis of polyunsaturated fatty acids and their related byproducts. [18F]FNDP is a radiotracer developed for use with positron emission tomography (PET) to image sEH, which has been applied to imaging sEH in the brains of healthy individuals. Here, we report the test-retest repeatability of [18F]FNDP brain PET binding and [18F]FNDP whole-body dosimetry in healthy individuals. METHODS: Seven healthy adults (4 men, 3 women, ages 40.1 ± 4.6 years) completed [18F]FNDP brain PET on two occasions within a period of 14 days in a test-retest study design. [18F]FNDP regional total distribution volume (VT) values were derived from modeling time-activity data with a metabolite-corrected arterial input function. Test-retest variability, mean absolute deviation, and intraclass correlation coefficient (ICC) were investigated. Six other healthy adults (3 men, 3 women, ages 46.0 ± 7.0 years) underwent [18F]FNDP PET/CT for whole-body dosimetry, which was acquired over 4.5 h, starting immediately after radiotracer administration. Organ-absorbed doses and the effective dose were then estimated. RESULTS: The mean test-retest difference in regional VT (ΔVT) was 0.82 ± 5.17%. The mean absolute difference in regional VT was 4.01 ± 3.33%. The ICC across different brain regions ranged from 0.92 to 0.99. The organs with the greatest radiation-absorbed doses included the gallbladder (0.081 ± 0.024 mSv/MBq), followed by liver (0.077 ± 0.018 mSv/MBq) and kidneys (0.063 ± 0.006 mSv/MBq). The effective dose was 0.020 ± 0.003 mSv/MBq. CONCLUSION: These data support a favorable test-retest repeatability of [18F]FNDP brain PET regional VT. The radiation dose to humans from each [18F]FNDP PET scan is similar to that of other 18F-based PET radiotracers.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Du Y, Coughlin JM, Amindarolzarbi A, et al. [18F]FNDP PET neuroimaging test-retest repeatability and whole-body dosimetry in humans. Eur J Nucl Med Mol Imaging. 2023. PMID: 37458759. doi:10.1007/s00259-023-06331-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。